Compounds | UP (ED50) | DBP (ED25) | Ratio |
---|---|---|---|
Rec 15/2739 | 2.4 (1.7–3.3) | 243 (151–391) | 101.25 |
Rec 15/2869 | 9.5 (6.9–13) | 1065 (822–1382) | 112.11 |
Rec 15/2841 | 1.8 (1.4–2.2) | 97 (56–166) | 53.89 |
Rec 15/2802 | 5.7 (4.7–6.9) | 141 (104–192) | 24.74 |
Rec 15/2636 | 10 (7.9–13) | 6.2 (3.8–10) | 0.62 |
Prazosin | 3.6 (3.1–4.2) | 6.6 (4.2–10) | 1.83 |
Rec 15/2627 | 31 (25–37) | 23 (18–29) | 0.74 |
Alfuzosin | 52 (36–77) | 372 (265–521) | 7.15 |
Terazosin | 21 (15–29) | 61 (42–90) | 2.90 |
Tamsulosin | 1.1 (0.9–1.3) | 11 (6.9–21) | 10.00 |
Phentolamine | 13 (7–22) | 124 (90–173) | 9.54 |
SNAP 5089 | 310 (146–657) | >3000 | >10.00 |
Data represent the active doses (expressed in micrograms per kilogram and 95% confidence limits) inhibiting by 50% the urethral contractions induced by NE (UP), the doses active (in micrograms per kilogram and 95% confidence limits) in lowering DBP by 25% and the ratio between the active doses (DBP/UP; selectivity index).